NSE · MANKIND
Mankind Pharma Limited
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹2,582 Cr with net profit ₹714 Cr — a 27.64% net margin, versus 13.07% the period before.
Shareholding
As of 2026-06-30
- Promoter72.63%
- Public2.53%
- FII9.45%
- DII15.39%
1,66,715 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 1.4× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Pharmaceuticals - Indian - Bulk Drugs & Formln · ranked #5 of 102 by market cap · medians across 49 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | ₹4,77,444 Cr | 176.1 | 5.71 | 13.74% | 19.72% |
| Cipla Ltd. | ₹1,19,101 Cr | 214.6 | 3.46 | 11.27% | 14% |
| Zydus Lifesciences Ltd. | ₹1,11,990 Cr | 88.75 | 4.13 | 18.59% | 18.86% |
| Lupin Limited | ₹1,11,885 Cr | 19.67 | 4.98 | 23.76% | 19.4% |
| Mankind Pharma Limited(this company) | ₹1,07,077 Cr | 192.91 | 6.57 | 11.74% | 13.4% |
| Laurus Labs Limited | ₹96,246 Cr | 88.01 | 18.16 | 16.77% | 15.04% |
| Dr Reddys Laboratories Ltd. | ₹95,344 Cr | 431.06 | 2.52 | 0.11% | 0.12% |
| Aurobindo Pharma Ltd. | ₹92,388 Cr | 100.3 | 2.44 | 9.25% | 10.5% |
| Biocon Ltd. | ₹69,837 Cr | 545.38 | 2.05 | 1.14% | 2.3% |
| Alkem Laboratories Ltd. | ₹67,823 Cr | 286.92 | 4.91 | 16.66% | 15.65% |
AI analysis
AI-generated · google/gemini-2.5-flashMankind Pharma Limited is listed with a market capitalization of Rs 105967 Cr. The company reported revenue of Rs 14636.43 Cr with a growth of 19% and a net profit margin of 13.4%. Its P/E ratio stands at 190.91, and EPS is Rs 48.78. The company's debt-to-equity ratio is 0.48.
Positives
- +Revenue grew by 19% to Rs 14636.43 Cr.
- +The profit margin is 13.4% of revenue.
- +The debt-to-equity ratio is 0.48, indicating moderate leverage.
- +Promoter holding of 72.6304% is substantial.
- +There are no promoter shares pledged.
Negatives
- −The P/E ratio is 190.91, which may indicate a high valuation.
- −Promoter holding decreased from 76.5% in December 2023 to 72.6304% in June 2026.
- −Public shareholding decreased from 7.26409999999998% in December 2023 to 2.52730000000001% in June 2026.
Financial Performance
In the period ending March 2026, Mankind Pharma Limited recorded revenue of Rs 14636.43 Cr, marking a 19% growth. The company's net profit for the same period was Rs 1912.93 Cr. Quarterly revenue for March 2026 was Rs 3442.93 Cr with a net profit of Rs 554.35 Cr. The EBITDA for March 2026 was Rs 821.09 Cr.
Profitability & Returns
Mankind Pharma Limited achieved a profit margin of 13.4%. The Return on Equity (ROE) for the company is 11.74%, and the Return on Capital Employed (ROCE) is 13.126%. The basic EPS stands at Rs 48.78. The P/E ratio is 190.91.
Balance Sheet
The company maintains a debt-to-equity ratio of 0.48. The book value per share is Rs 394.69. No information regarding other specific balance sheet items is provided in the data.
Ownership & Pledges
The public shareholding stands at 2.5273%. The total institutional holding is 24.8423%. There are no promoter pledges reported.
Shareholding History
Promoter holding has decreased from 74.88% in March 2024 to 72.6304% in June 2026. DII holding has increased from 11.1384% in March 2024 to 15.389% in June 2026. FII holding has decreased from 9.8736% in March 2024 to 9.4533% in June 2026. The number of shareholders has increased from 135,116 in March 2024 to 166,715 in June 2026.
Data as of — price: 2026-07-30 · financials: Mar 26 · shareholding: Jun 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.